 | |
| Cipla | |
| Formerly | Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984) |
| Company type | Public |
| BSE: 500087 NSE: CIPLA NSE NIFTY 50 constituent | |
| ISIN | INE059A01026 |
| Industry | Pharmaceuticals |
| Founded | 1935 (90 years ago) (1935) |
| Founder | Khwaja Abdul Hamied |
| Headquarters | Mumbai,Maharashtra, India |
Area served | Worldwide |
Key people |
|
| Products | |
| Revenue |  ₹27,548 crore (US$3.3 billion) (2025) |
| ₹7,128 crore (US$840 million) (2025) | |
| ₹5,273 crore (US$620 million) (2025) | |
| Total assets | ₹37,387 crore (US$4.4 billion) (2025) |
| Total equity | ₹31,289 crore (US$3.7 billion) (2025) |
Number of employees | 27,764 (March 2024)[1] |
| Subsidiaries | Invagen Pharmaceuticals |
| Website | www.cipla.com |
| Footnotes / references Financials as of 31 March 2025[update].[2][3] | |
Cipla Limited is an Indianmultinationalpharmaceutical company headquartered inMumbai. Cipla primarily focuses on developing medication to treatrespiratory disease,cardiovascular disease,arthritis,diabetes,depression,paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer inIndia.[4][5]
After meetingMahatma Gandhi in the early 1920s,Khwaja Abdul Hamied decided to contribute to theSwadeshi movement by pursuing a doctorate in chemistry. In 1935, Hamied founded Cipla as the Chemical, Industrial & Pharmaceutical Laboratories inMumbai.[6][7] DuringWorld War II, the company became the largest supplier ofquinine andVitamin B12 forAllied soldiers.[8] The company name shortened to its current form in July 1984.[7] Upon Hamied's death in 1972, his sonYusuf Hamied, a Cambridge-educated chemist, took over the company.[8]
In 1995, Cipla launchedDeferiprone, the world's first oral iron chelator.[6] In 1999, Cipla joined theIndian Pharmaceutical Alliance as a founding member in an effort to promote the development of generic drugs in India.[9][10] During theAIDS epidemic in the early 2000s, Hamied reverse-engineered a three-drugantiretroviral medication that was sold for about $12,000 per year to create a cheaper version that sold for $304 per year.[11] This drug was sold to African charities and governments. It is estimated that "at one time, as much as 40 percent of the AIDS patients in poor countries took Cipla drugs".[11]
During theavian flu pandemic in 2006, Cipla was able to reverse-engineer the drug Tamiflu and sell it for significantly lower prices.[9] In 2013, Cipla acquired theSouth African company Cipla-Medpro. Its name was changed to Cipla Medpro South Africa Limited and was kept as a subsidiary.[12][13] At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company.[12] The company had been founded in 2002 under the name Enaleni Pharmaceuticals Ltd.[14] In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company;[15] in 2008, it changed its name to Cipla-Medpro.[16] In September 2023, it was announced Cipla South Africa had acquired theMidrand-headquartered healthcare products manufacturer, Actor Pharma.[17]
In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.[18] In 2019, Cipla entereddigital therapeutics by partnering with Wellthy Therapeutics inIndia and Brandmed inSouth Africa.[19] In April 2024, Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore.[20]
Cipla sellsactive pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products,[21] including the anti-depressantescitalopram oxalate,lamivudine, andfluticasone propionate.[22] Cipla is the world's largest manufacturer ofantiretroviral drugs.[21][23]
In July 2020, the company announced the introduction ofGilead Sciences'Remdesivir under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company andDCGI approval for "restricted emergency use" inCOVID-19 treatment of patients in critical condition.[24][25][26]
Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.[27][28] Exports accounted for 48%₹4,948 crore (equivalent to₹84 billion or US$990 million in 2023) of its revenue for the 2013–14 fiscal year.[29] Cipla spent₹517 crore (5.4% of their revenue) in the 2013–14 fiscal year on R&D activities.[29] The primary focus areas for R&D were development of new formulations, drug-delivery systems, and APIs. Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.[citation needed]
The equity shares of Cipla are listed on theBombay Stock Exchange,[30] where it is a constituent of theBSE SENSEX index,[31] and theNational Stock Exchange of India,[32] where it is a constituent of theCNX Nifty.[33] ItsGlobal Depository Receipts (GDRs) are listed on theLuxembourg Stock Exchange.[29]
As of December 31, 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares.SBI Mutual Fund,LIC etc. are the largest non-promoter shareholders in the Company.[34] In January 2024, Samina Hamied resigned from her position as the Executive Vice Chairperson of Cipla. She continued to serve the company as a non-executive director subject to rotational retirement.[citation needed]
| Shareholders (as on 31-December-2022) | Shareholding[35] |
|---|---|
| Promoter Group | 33.61% |
| Mutual funds | 14.09% |
| Financial Institution/Banks/Insurance | 4.96% |
| Foreign Institutional Investors (FII) | 28.39% |
| Corporate Bodies | 0.53% |
| Individuals | 14.72% |
| NRIs/OCBs | 0.88% |
| ADRs/GDRs | NIL |
| Others | 2.82% |
| Total | 100.00% |
In August 2007, Cipla launched anemergency contraception drug "i-pill" soldover the counter,.[43] The drug sparked controversy as it was available without prescription and contained a large amount of API per dosage.[44][45]
In the late 1960s, Cipla began manufacturing a new, patented drug,propranolol, without the permission of the drug's patent holder,Imperial Chemical Industries; a protest was filed with the Indian government. The CEO of Cipla pressured thegovernment of Indira Gandhi to change India'spatent laws to eliminate patents that directly covered drugs, and instead to allow only patents that coveredmethods to make drugs[46] so that Cipla could produce low-priced generic drugs. Since then, Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries.[47] The changes made led to criticism of both India's patent laws and Cipla.[48] India reinstated patents on drugs in 2005.[46]
{{cite news}}: CS1 maint: numeric names: authors list (link) NIFTY 50 companies of India | |
|---|---|
|
| International | |
|---|---|
| National | |
| Other | |
